Amgen Ventures

Investor type Venture Capital
Founders Leroy Hood Marvin Caruthers

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 84
Average round size
info
The average size of a deal this fund participated in
$55M
Portfolio companies 54
Rounds per year 4.94
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.36
Exits 25
Key employees 1
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 2004 was created Amgen Ventures, which is appeared as VC. The main department of described VC is located in the San Francisco. The fund was located in North America if to be more exact in United States.

The fund was created by Leroy Hood, Marvin Caruthers. Besides them, we counted 1 critical employee of this fund in our database.

Among the most popular fund investment industries, there are Health Care, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Alector, TetraLogic Pharmaceuticals, Senti Biosciences. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Amgen Ventures, startups are often financed by Alta Partners, SV Health Investors, ARCH Venture Partners. The meaningful sponsors for the fund in investment in the same round are OVP Venture Partners, HealthCare Ventures, Alta Partners. In the next rounds fund is usually obtained by HealthCare Ventures, Alta Partners, Remeditex Ventures.

This Amgen Ventures works on 1 percentage points less the average amount of lead investments comparing to the other organizations. The typical startup value when the investment from Amgen Ventures is 100-500 millions dollars. Considering the real fund results, this VC is 11 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2014. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Amgen Ventures:
Typical Co-investors
Amgen Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Amgen Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Genome Medical

Genetics
Health Care
Life Science
Medical
$60M30 Aug 2021 South San Francisco, California, United States

GPB Scientific

Biotechnology
Health Care
Health Diagnostics
Medical Device
$18M27 May 2021 Richmond, Virginia, United States

Akili Interactive Labs

Biotechnology
Health Care
Medical
Medical Device
Neuroscience
Therapeutics
$110M26 May 2021 Boston, Massachusetts, United States

Hummingbird Bioscience

Biotechnology
Health Care
Therapeutics
$125M18 May 2021 Singapore, Central Region, Singapore

Senti Biosciences

Biotechnology
Health Care
Medical
Therapeutics
$105M06 Jan 2021 South San Francisco, California, United States

DJS Antibodies

Biotechnology
Health Care
$8M22 Dec 2020 Oxford, England, United Kingdom

Carmot Therapeutics

Biotechnology
Health Care
Therapeutics
$47M30 Sep 2020 San Francisco, California, United States

BeiGene

Biotechnology
Health Care
Life Science
Medical
$2B12 Jul 2020 Changping District, Beijing, China

Syapse

Big Data
Bioinformatics
Cloud Computing
Health Care
Information Services
Information Technology
SaaS
$30M28 May 2020 San Francisco, California, United States
News
Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama

– Saama technologies announced a strategic growth investment and will be acquired by Carlyle.
– Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
– As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics.
– Carlyle has made a strategic growth investment and will acquire a majority stake in the Company.
– A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.

Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Amgen Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: